AI assistant
KALA BIO, Inc. — Director's Dealing 2023
Jun 24, 2023
35091_dirs_2023-06-23_87aaf492-a7a6-478e-9a3a-6356a21e67a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2023-06-22
Reporting Person: KOVEN ANDREW I (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-22 | Common Stock | A | 7515 | — | Acquired | 10772 | Direct |
| 2023-06-22 | Common Stock | A | 1400 | — | Acquired | 12172 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-22 | Stock Option (right to buy) | $14.56 | A | 10020 | Acquired | 2033-06-21 | Common Stock (10020) | Direct |
| 2023-06-22 | Stock Option (right to buy) | $14.56 | A | 3150 | Acquired | 2033-06-21 | Common Stock (3150) | Direct |
Footnotes
F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
F2: Includes 10,772 unvested RSUs.
F3: Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
F4: Includes 12,172 unvested RSUs.
F5: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
F6: This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.